Sorriso Pharmaceuticals picks up $31m Series A

Sorriso Pharmaceuticals, a provider of anti-inflammatory antibody therapy, has secured $31 million in Series A financing.

22 December 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles